Publications

Search Publications
Export 17 results:
Author [ Title(Desc)] Year
Filters: Keyword is Hepatitis B virus  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
A
Winer BY, Gaska JM, Lipkowitz G, Bram Y, Parekh A, Parsons L, et al. Analysis of Host Responses to Hepatitis B and Delta Viral Infections in a Micro-scalable Hepatic Co-culture System. Hepatology. 2020 ;71(1):14-30.
Ploss A, Strick-Marchand H, Li W. Animal Models for Hepatitis B: Does the Supply Meet the Demand?. Gastroenterology. 2021 ;160(5):1437-1442.
Liu Y, Maya S, Ploss A. Animal Models of Hepatitis B Virus Infection-Success, Challenges, and Future Directions. Viruses. 2021 ;13(5).
C
Wei L, Ploss A. Core components of DNA lagging strand synthesis machinery are essential for hepatitis B virus cccDNA formation. Nat Microbiol. 2020 ;5(5):715-726.
H
Wei L, Ploss A. Hepatitis B virus cccDNA is formed through distinct repair processes of each strand. Nat Commun. 2021 ;12(1):1591.
L
Winer BY, Huang TS, Pludwinski E, Heller B, Wojcik F, Lipkowitz GE, et al. Long-term hepatitis B infection in a scalable hepatic co-culture system. Nat Commun. 2017 ;8(1):125.
Biswas S, Rust LN, Wettengel JM, Yusova S, Fischer M, Carson JN, et al. Long-term hepatitis B virus infection of rhesus macaques requires suppression of host immunity. Nat Commun. 2022 ;13(1):2995.
M
Maya S, Ploss A. Master of Disguise: Hepatitis Delta Virus Packaging and Spread Facilitated by Diverse Viral Envelope Proteins. Hepatology. 2020 ;71(1):380-382.
Shekhtman L, Cotler SJ, Ploss A, Dahari H. Mathematical modeling suggests that entry-inhibitor bulevirtide may interfere with hepatitis D virus clearance from circulation. J Hepatol. 2022 ;76(5):1229-1231.
Wei L, Ploss A. Mechanism of Hepatitis B Virus cccDNA Formation. Viruses. 2021 ;13(8).
N
Yau T, Hsu C, Kim T-Y, Choo S-P, Kang Y-K, Hou M-M, et al. Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis. J Hepatol. 2019 ;71(3):543-552.
P
Winer BY, Shirvani-Dastgerdi E, Bram Y, Sellau J, Low BE, Johnson H, et al. Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection. Sci Transl Med. 2018 ;10(447).
R
Winer BY, Huang T, Low BE, Avery C, Pais M-A, Hrebikova G, et al. Recapitulation of treatment response patterns in a novel humanized mouse model for chronic hepatitis B virus infection. Virology. 2017 ;502:63-72.
Wei L, Ploss A. Rise above the stress-Endoplasmic reticulum stress and autophagy enhance the release of hepatitis B virus subparticles. Hepatology. 2022 ;75(2):248-251.
S
Shirvani-Dastgerdi E, Winer BY, Celià-Terrassa T, Kang Y, Tabernero D, Yagmur E, et al.. Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. J Hepatol. 2017 ;67(2):246-254.
Akkina R, Barber DL, Bility MT, Bissig K-D, Burwitz BJ, Eichelberg K, et al. Small Animal Models for Human Immunodeficiency Virus (HIV), Hepatitis B, and Tuberculosis: Proceedings of an NIAID Workshop. Curr HIV Res. 2020 ;18(1):19-28.
Han Y, Donovan J, Rath S, Whitney G, Chitrakar A, Korennykh A. Structure of human RNase L reveals the basis for regulated RNA decay in the IFN response. Science. 2014 ;343(6176):1244-8.